- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 12
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 12, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 12.
Number 5: On the same day that the President released his budget proposal that called for $2 billion less in funding for the National Institutes of Health than allocated by Congress, a new paper argued that a reduction in funding would significantly delay the emergence of new drugs.
Number 4: Roche has released phase 2 data for a novel drug that could compete with biosimilars of anti-vascular endothelial growth factor therapies.
Number 3: The White House’s Council of Economic Advisors said in a new white paper that the FDA should finalize biosimilar interchangeability guidelines that are easy and inexpensive to adhere to in order to promote competition.
Number 2: South Dakota became the latest state to pass legislation governing the substitution of interchangeable biosimilars for their reference products.
Number 1: Celltrion has received authorization to market its biosimilar trastuzumab, Herzuma, in the European Union.
Also this week, attorneys George Yu and Christopher Bruno, both of Schiff Hardin, explained how the Supreme Court’s eventual decision in the ongoing Oil States case could affect the biologics industry.
Finally, last week, our e-newsletter asked whether the United States should follow Australia’s lead by not using 4-letter suffixes in the names of biosimilars and biologics.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
